GEN Exclusives

More »

GEN News Highlights

More »
May 28, 2009

Novartis Offers 28% More for Increased Control over India Operations

  • Novartis is upping its offer to acquire an additional stake in Novartis India by about 28%, bringing the value of the deal up to Rs. 5.64 billion, or roughly $118.48 million. Novartis says this is its final proposal.

    If the transaction goes through, Novartis would enjoy more control over Novartis India and would decrease dividends paid to minority shareholders in the subsidiary.

    Shares of Novartis India surged 20% to reach Rs. 467.50 in morning trading on the Bombay Stock Exchange. The firm is now trading over the current acquisition price being offered of Rs. 450 per share.

    In March Novartis sought to buy an additional 39% of its Indian subsidiary for Rs. 351 per share. The company currently owns 50.9% of Novartis India.

    Today’s offer comes at Rs. 450 per share, a 63% premium to the closing share price of Rs. 275.6 the day before the initial proposal was made.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »